Ischemic Stroke
Conditions
Interventions
This is a randomized, controlled, double-blind clinical trial with two arms. A total of 36 participants diagnosed with ischemic stroke will be included, treated at the Hospital de Urgência de Sergipe,
Sponsors
Universidade Federal de Sergipe
Hospital de Urgência de Sergipe (HUSE)
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Adults aged 18 years or older; of both sexes; with a diagnosis of ischemic stroke confirmed clinically or by neuroimaging; with symptom onset within 24 hours; who agree to participate by signing the informed consent form by the participant or legal representative
Exclusion criteria
Exclusion criteria: Participants with a diagnosis of hemorrhagic stroke; with more than 24 hours since symptom onset; with a diagnosis of Parkinson’s disease; with neoplasms; with diagnosis of encephalic infection; pregnant women; with a history of allergy to any component of the medications used in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the National Institutes of Health Stroke Scale (NIHSS) score between baseline and follow-up assessments comparing the intervention group (trimetazidine plus standard therapy) with the control group (standard therapy) | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in functional disability assessed by the Modified Rankin Scale; mortality during follow-up; occurrence of hemorrhagic events; length of hospital stay comparing the intervention group (trimetazidine plus standard therapy) and the control group (standard therapy) | — |
Countries
BR
Contacts
Public ContactPhillip Nicolau de Almeida
Universidade Federal de Sergipe
Outcome results
None listed